Standard Glass Lining Technology IPO opens
Standard Glass Lining IPO GMP Day 1 Live: Standard Glass Lining IPO opens today. Check GMP, Price band, Key dates and other details
The ₹1,250 crore issue includes a fresh equity offering of up to ₹210 crore and an offer for sale of up to 1.42 crore shares, with bidding open until January 8. Ahead of the opening, the company raised ₹123 crore from anchor investors.
Standard Glass Lining IPO: Retail, NII Portions Fully Subscribed; Check GMP Today
Unlisted shares of Standard Glass Lining Ltd continue to trade at Rs 237 apiece in the grey market, which is a 69.29 per cent premium over the upper IPO price of Rs 140. It indicates a robust listing gain for investors on January 13.
The restaurant group announced Tuesday that Jose Alberto Dueñas is stepping down. Chief financial officer Paul Carbone, a ...
Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...
Hosted on MSN2m
Quadrant Future Tek IPO: Issue subscribed 48.99 times on day 2; check subscription status, other key detailsQuadrant Future Tek initial public offering (IPO) opened for subscription on Tuesday, January 7. On the second day of ...
Medical technology firm Brainlab AG has asked for bank proposals for its potential initial public offering in Frankfurt, ...
Simpson Thacher partners offer IPO tips for private companies, noting that having an independent board and the correct ...
Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in ...
Nice One Beauty Digital Marketing Co. surged in its debut after a $320 million initial public offering in Riyadh, the latest ...
Smithfield Foods on Monday made public its paperwork for its New York initial public offering as the maker of Farmland bacon ...
Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to ...
Although 2024 was an exceptionally lackluster year for new public offerings, the IPO market could gain momentum in 2025. In ...
Drug developer Maze Therapeutics Inc.'s rollercoaster ride is leading to the Bay Area's first biotech IPO filing of 2025.
Proceeds from the initial public offering (IPO) will be used to repay debt, redeem equity interests and support general ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback